Studying neutralizing capacities of the 4 mAb regimens in an ACE2 neutralization assay, we first showed a highly significant difference by which these mAbs neutralize 5 past or currently circulating SARS-CoV-2 variants ( Figure 4 and Supplemental Figure 4 ).
← all excerpts
Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments.
1
—
—